Abstract | BACKGROUND: Patients with poor-risk Waldenström's macroglobulinemia have suboptimal response and early post-treatment relapse with conventional therapies. Hence, new therapeutic approaches such as allogeneic stem cell transplantation should be evaluated in these patients. DESIGN AND METHODS: We examined the long-term outcome of allogeneic stem cell transplantation in Waldenström's macroglobulinemia by studying the records of 24 patients reported in the SFGM-TC database and one transplanted in the bone marrow unit in Hamburg. RESULTS: Median age at the time of transplant was 48 years (range, 24-64). The patients had previously received a median of 3 lines of therapy (range, 1-6) and 44% of them had refractory disease at time of transplant. Allogeneic stem cell transplantation after myeloablative (n=12) or reduced-intensity (n=13) conditioning yielded an overall response rate of 92% and immunofixation-negative complete remission in 50% of evaluable patients. With a median follow-up of 64 months among survivors (range, 11-149 months), 5-year overall survival and progression-free survival rates were respectively, 67% (95% CI: 46-81) and 58% (95% CI: 38-75). The 5-year estimated risk of progression was 25% (95% CI: 10-36%), with only one relapse among the 12 patients who entered complete remission, versus 5 in the 12 patients who did not. Only one of the 6 relapses occurred more than three years post-transplant. CONCLUSIONS:
|
Authors | Alice Garnier, Marie Robin, Fabrice Larosa, Jean-Louis Golmard, Steven Le Gouill, Valérie Coiteux, Reza Tabrizi, Claude-Eric Bulabois, Victoria Cacheux, Mathieu Kuentz, Brigitte Dreyfus, Peter Dreger, Bernard Rio, Marie-Pierre Moles-Moreau, Karin Bilger, Jacques-Olivier Bay, Véronique Leblond, Didier Blaise, Olivier Tournilhac, Nathalie Dhédin |
Journal | Haematologica
(Haematologica)
Vol. 95
Issue 6
Pg. 950-5
(Jun 2010)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 20081058
(Publication Type: Comparative Study, Journal Article)
|
Topics |
- Adult
- Disease-Free Survival
- Female
- Follow-Up Studies
- France
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Male
- Middle Aged
- Remission Induction
- Retrospective Studies
- Risk Factors
- Societies, Medical
- Time Factors
- Transplantation, Homologous
- Treatment Outcome
- Waldenstrom Macroglobulinemia
(mortality, pathology, surgery)
- Young Adult
|